Divi's Laboratories Limited (DIVISLAB)

Healthcare · Pharmaceuticals & Biotechnology · NSE · Updated 14 July 2026

₹6,938.5 ↑ 2.36% (1Y)

🎯 Key Takeaways

Divi's Laboratories is in a mature growth phase with strong profitability and cash generation, operating in the high-margin active pharmaceutical ingredients (API) segment. The company maintains a pristine balance sheet with zero debt and robust returns, but faces near-term tax uncertainty from a ₹570.
Revenue declined 4.1% QoQ to ₹2,604 in Q3FY26.
⚠️ The ₹570.51 crore draft tax order with potential penalties under Section 270A poses a material financial and reputational risk, pending appeal outcome

Market Cap

₹1.79 L Cr

P/E Ratio

72.4

P/B Ratio

11.99

ROE

16.6%

ROCE

22.1%

Debt/Equity

0.00

Div Yield

0.00%

Promoter

0.0%

✨ Ask AI About DIVISLAB 📊 Interactive Charts

📖 The Story

Divi's Laboratories is in a mature growth phase with strong profitability and cash generation, operating in the high-margin active pharmaceutical ingredients (API) segment. The company maintains a pristine balance sheet with zero debt and robust returns, but faces near-term tax uncertainty from a ₹570.51 crore draft assessment order. Management is focused on capital allocation through dividends and strategic reinvestment, while navigating regulatory and international market dynamics.

📰 What's Happening

The most recent development was the Board's approval of a ₹30 per share dividend for FY2025-26 (1,500% payout), up from ₹20 previously, contingent on AGM approval on August 10, 2026, with payout scheduled after August 14, 2026. This follows a pattern of increasing shareholder returns. Earlier, the company filed unaudited Q3 FY26 results (ending December 31, 2025) via regulatory newspaper clippings on February 12, 2026, though financial details were not included in the filing. Management also disclosed a ₹74 crore exceptional charge related to labour code impacts during Q3 FY26, which affected PAT despite revenue growth. Additionally, a Draft Assessment Order from the Income Tax Authority dated March 20, 2026 proposed ₹570.51 crores in additions for FY2022-23, triggering penalty proceedings under Section 270A.

Source: Stock Announcements

📊 Quarterly Results (₹ Cr)

Metric	Q4FY24	Q1FY25	Q2FY25	Q3FY25	Q4FY25	Q1FY26	Q2FY26	Q3FY26
Revenue	2,303	2,118	2,338	2,319	2,585	2,410	2,715	2,604
Operating Profit	810	701	822	825	972	848	1,033	904
OPM %	31.7%	29.4%	30.6%	32.0%	34.3%	30.3%	32.7%	34.2%
Net Profit	538	430	510	589	662	545	689	583
EPS	₹20.25	₹16.20	₹19.20	₹22.20	₹24.93	₹20.49	₹25.97	₹21.98

Divi's has demonstrated consistent revenue growth, with Q3FY26 revenue of ₹2,604 crores up 12.1% YoY from ₹2,319 crores in Q3FY25, and nine-month FY26 revenue up 14.8% YoY to ₹8,081 crores. However, profitability has shown signs of pressure, with Q3FY26 PAT declining to ₹583 crores from ₹589 crores YoY, partly due to a ₹74 crore labour code impact and higher input costs. Operating margins remain stable at 34.2% in Q3FY26, but have slightly compressed from peaks seen in prior quarters. The sequential revenue trend shows moderation, with Q3FY26 (₹2,604 cr) slightly below Q2FY26 (₹2,715 cr), suggesting possible demand softness or inventory digestion. Despite this, the company continues to expand capacity and maintain strong execution in its domestic and international API markets.

🔮 Management Outlook & What's Next

Management has not provided explicit forward guidance on revenue or margins in the latest filings, but indicated that it will continue monitoring the finalisation of Central and State Rules and clarifications on the new Labour Codes, with potential updates on employee benefits liability when available. The Board's declaration of a significantly increased dividend signals confidence in cash flow generation and financial stability, contingent on AGM approval. Management also plans to evaluate and file an appeal against the Draft Assessment Order within the stipulated timeframe, expressing intent to challenge the proposed tax additions and penalty proceedings.

Extracted from official company announcements. Not StockFin.ai's opinion.

🏦 Balance Sheet (₹ Cr)

Item	2023-2024	2023-2024	2024-2025	2024-2025	2025-2026
Equity Capital	53	53	53	53	53
Reserves	12,624	13,518	13,664	14,916	15,360
Borrowings	2	0	5	2	89
Total Liabilities	1,606	1,899	1,869	1,963	2,738
Fixed Assets	4,648	4,733	4,652	5,437	5,672
Investments	80	82	85	65	67
Total Assets	14,283	15,470	15,586	16,932	18,151

The balance sheet reflects a strong capital structure with equity of ₹53 crores and reserves of ₹15,360 crores as of 2025-26, up from ₹14,916 crores in the prior year. Borrowings remain negligible at ₹89 crores, down from ₹2 crores previously, underscoring a conservative capital allocation strategy. Total assets have grown steadily to ₹18,151 crores, driven by reinvestment of cash flows. The company is clearly reinvesting profits into operations and reserves while maintaining a near-zero debt profile, supporting long-term financial resilience and flexibility.

💰 Cash Flow Statement (₹ Cr)

Item	2020-2021	2020-2021
Operating	+1,158	+1,947
Investing	+580	+75
Financing	-34	-35
Net Cash Flow	—	—

⚖️ Peer Comparison — Pharmaceuticals & Biotechnology

Company	MCap (₹ Cr)	P/E	ROCE	ROE	D/E
Sun Pharmaceutical Industries Limited	4.51 L Cr	41.3	20.3%	15.1%	0.03
Divi's Laboratories Limited	1.79 L Cr	72.4	22.1%	16.6%	0.00
Torrent Pharmaceuticals Limited	1.49 L Cr	80.1	—	—	—
Cipla Limited	1.16 L Cr	25.4	19.4%	14.6%	0.00
Dr. Reddy's Laboratories Limited	1.12 L Cr	20.0	19.7%	16.6%	0.12
Lupin Limited	1.04 L Cr	36.2	—	—	—
Mankind Pharma Limited	1.03 L Cr	49.2	—	—	—
Zydus Lifesciences Limited	1.02 L Cr	22.5	—	—	—
Aurobindo Pharma Limited	87,806	25.3	—	—	—
Laurus Labs Limited	71,455	356.8	—	—	—

🔗 Peer Stock Analyses

SUNPHARMA TORNTPHARM CIPLA DRREDDY LUPIN

⚠️ Risk Factors

1. The ₹570.51 crore draft tax order with potential penalties under Section 270A poses a material financial and reputational risk, pending appeal outcome. 2. Ongoing uncertainty around international regulatory environments, particularly in the US and EU markets, could impact export growth. 3. Rising input costs and margin pressure, as seen in the ₹74 crore labour code impact and sequential revenue softness, may challenge profitability if not managed. 4. Compliance with evolving labour laws and potential liabilities from past adjustments could lead to additional contingent liabilities.

📋 Recent Filings

🧠 Analyst's Read

Divi's Laboratories remains a fundamentally strong company with durable profitability and a clean balance sheet, but is currently navigating a critical tax dispute that introduces near-term volatility. Investors should monitor the outcome of the tax appeal and any updates on international demand trends, especially in regulated markets. The sustainability of margin performance and ability to maintain growth amid pricing pressures will be key watchpoints in the coming quarters.

Based on filing content and financial data. Not a recommendation.

✨ Deep Dive with AI on DIVISLAB

Data sourced from stock announcements. Analysis generated by StockFin.ai.
For informational purposes only — not investment advice. Updated 2026-07-14.

📡 Get AI alerts when DIVISLAB files new disclosures

Track DIVISLAB filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track DIVISLAB — Free

Free account · 2 AI queries/day